Breakthrough treatment bolsters Crawford Healthcare

Breakthrough treatment bolsters Crawford Healthcare

A new treatment for chronic wounds, developed in the North West by Crawford Healthcare and the University of Manchester, could save the NHS over £125 million a year, following the success of a new study.

With over 5,000 major limb amputations taking place each year in England, at a cost of around £25,000 per operation, Crawford’s new silver-based wound dressing KerraContact Ag – developed in partnership with the University of Manchester – has prevented a near certain leg amputation at an NHS hospital following the failure of traditional antibiotic treatment.

“This is a real coup for Life Sciences in the North and is a spectacular example of how innovation in healthcare can be a key driver in the success of the Northern Powerhouse,” commented Richard Anderson, CEO of Crawford Healthcare.

The KerraContact Ag dressing features OxysaltTM, a new silver-based technology which Crawford Healthcare secured exclusive development rights to earlier this year, and is the first and only wound dressing to utilise the element in its most active state. Being 99.99% effective, the technology is the future of their product pipeline and they are anticipating huge growth when it hits the marketplace.

Crawford’s exclusive rights to the development of OxysaltTM within future wound care products is expected to further boost the company’s rapid growth. Over the last three years the Knutsford-based business has enjoyed 30 per cent average annual growth whilst establishing export operations in Europe and the US.

This development allows the firm to challenge the three market leaders, who are failing to innovate rapidly despite their resources.

Richard continued: “This exclusivity agreement strengthens our position as a new market leader with a cornerstone technology that will further enhance our rapid growth in recent years. We now have an unrivalled platform to tackle the issue of secondary infections faced by clinicians the world over, which will boost our portfolio significantly and bolster our global growth.

“Silver has been used to treat infection for thousands of years, but interest in it waned when antibiotics became widely available. With antibiotic resistance now a serious threat healthcare provision, silver is proving a real asset in this global battle and we expect it to be the cornerstone of modern wound care for decades to come.”